InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.440

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$361 US FDA sets PDUFA date for Maxigesic IV 1 May 2023 7:34AM $3.180 $3.440 risen by 8.18%
$361 AFT submits Maxigesic IV packaging data to the US FDA 18 Apr 2023 7:31AM $3.200 $3.440 risen by 7.50%
$361 NEW LICENSING AND APPROVALS 27 Mar 2023 7:31AM $3.250 $3.440 risen by 5.85%
$361 Maxigesic Rapid tablets gain US FDA approval 2 Mar 2023 9:39AM $3.250 $3.440 risen by 5.85%
$361 AFT to develop antibiotic eye drop 2 Feb 2023 7:30AM $3.350 $3.440 risen by 2.69%
$361 AFT announces Maxigesic IV distribution agreement for nine 24 Jan 2023 7:30AM $3.360 $3.440 risen by 2.38%
$361 2023 New Year letter to investors 9 Jan 2023 7:31AM $3.400 $3.440 risen by 1.18%
$361 221124 Interim results FY23H1 App 2 amended 24 Nov 2022 7:33AM $3.440 $3.440 fallen by 0%
$361 221124 Interim results FY23H1 presentation 24 Nov 2022 7:31AM $3.440 $3.440 fallen by 0%
$361 221124 Interim results FY23H1 interim report 24 Nov 2022 7:31AM $3.440 $3.440 fallen by 0%
$361 221124 Interim results FY23H1 App 2 24 Nov 2022 7:31AM $3.440 $3.440 fallen by 0%
$361 221124 Interim results FY23H1 release 24 Nov 2022 7:31AM $3.440 $3.440 fallen by 0%
$361 AFT to announce half year interim results on Nov 24 10 Oct 2022 2:31PM $2.990 $3.440 risen by 15.05%
$361 AFT update on Maxigesic IV US registration filing 2 Sep 2022 7:30AM $2.900 $3.440 risen by 18.62%
$361 AFT collaborates to develop birthmark medicine 1 Sep 2022 7:30AM $2.900 $3.440 risen by 18.62%
$361 Results of 2022 Annual Shareholder Meeting 5 Aug 2022 11:16AM $3.200 $3.440 risen by 7.50%
$361 2022 ASM presentation 5 Aug 2022 7:30AM $3.200 $3.440 risen by 7.50%
$361 2022 ASM address 5 Aug 2022 7:30AM $3.200 $3.440 risen by 7.50%
$361 AFP Completes Pascomer Clinical Study and Takes Back Rights 27 Jul 2022 7:30AM $3.690 $3.440 fallen by 6.78%
$361 Dr Doug Wilson to step down from AFT Board 22 Jul 2022 7:30AM $3.400 $3.440 risen by 1.18%
$361 RLG:&AFT Pharmaceutical OTC medicines launch in China-Upd 8 Jul 2022 9:58AM $3.240 $3.440 risen by 6.17%
$361 RLG:RLG & AFT launch OTC medicines online in China 7 Jul 2022 9:38AM $3.330 $3.440 risen by 3.30%
$361 AFT and RooLife launch OTC medicines online in China 7 Jul 2022 7:30AM $3.330 $3.440 risen by 3.30%
$361 Notice of Annual Meeting of Shareholders 2022 5 Jul 2022 7:31AM $3.330 $3.440 risen by 3.30%
$361 US FDA seeks more information on Maxigesic IV application 1 Jul 2022 12:47PM $3.330 $3.440 risen by 3.30%

126 - 150 of 546 results

Page 6 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.